Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted
 therapy will be candidates for the study.

 No additional treatment or intervention will be conducted except for blood sampling that will
 be limited to one time only.

 Blood samples (10 cc in volume) will be collected from all study participants once they
 provided written informed consent form. DNA will be extracted from peripheral blood samples
 using DNA isolation kit.
Inclusion Criteria:

 -  All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular
 targeted therapy will be candidates for the study